Adagene (ADAG) Accumulated Expenses (2019 - 2026)
Adagene (ADAG) posted quarterly Accumulated Expenses of $2790.8 billion for Q4 2025, down 0.9% year-over-year from $2816.0 billion in Q4 2024, and up 75913576.7% quarter-over-quarter from $3.7 million in Q2 2025.
Analysis
Adagene (ADAG) Accumulated Expenses (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Accumulated Expenses for 7 consecutive years, with $2790.8 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses fell 0.9% year-over-year to $2790.8 billion; the TTM figure through Dec 2025 stood at $2790.8 billion (down 0.9% YoY), while the FY2025 annual figure was $2790.8 billion, down 0.9% from the prior year.
- Accumulated Expenses rose to $2790.8 billion in Q4 2025 per ADAG's latest filing, from $3.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $4237.6 billion in Q2 2022 and bottomed at $2.7 million in Q2 2024.
- Historically, Accumulated Expenses has averaged $1889.3 billion across 5 years, with a median of $2803.4 billion in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 119089996.15% — and 2024, when it sank 100.0%.
- Adagene's Accumulated Expenses stood at $4.4 million in 2021, then soared by 73364383.31% to $3212.8 billion in 2022, then fell by 6.58% to $3001.5 billion in 2023, then retreated by 6.18% to $2816.0 billion in 2024, then fell by 0.9% to $2790.8 billion in 2025.
- Business Quant data shows ADAG's Accumulated Expenses at $2790.8 billion in Q4 2025, $3.7 million in Q2 2025, and $2816.0 billion in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Adagene | 213.60 Mn | 213.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Jun 30, 2025 | 3.68 Mn |
| Dec 31, 2024 | 2.82 Mn |
| Jun 30, 2024 | 2.66 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Jun 30, 2023 | 2.83 Mn |
| Dec 31, 2022 | 3.21 Mn |
| Jun 30, 2022 | 4.24 Mn |
| Dec 31, 2021 | 4.38 Mn |
| Jun 30, 2021 | 3.56 Mn |
| Dec 31, 2020 | 6.06 Mn |
| Dec 31, 2019 | 2.54 Mn |